Literature DB >> 20395799

Low scar abdominoplasty with inferior positioning of the umbilicus.

Amy S Colwell1, Dzifa Kpodzo, G Gregory Gallico.   

Abstract

Miniabdominoplasty with umbilical free float has received little attention in the literature in 15 years and has been criticized for an abnormally low umbilicus. We hypothesized the umbilicus in women presenting for abdominal contouring is positioned higher than ideal and thus may benefit from lowering. In addition, we felt modifications of the original umbilical float technique would improve aesthetic results. A retrospective review identified 60 patients aged 34 to 56 who had abdominoplasty with umbilical fascial transection and inferior positioning. Technical modifications included low placement of a full transverse abdominal scar, abdominal flap undermining to the rib cage, more inferior umbilical repositioning, flank liposuction, and plication of diastasis recti from xiphoid to pubis. Patients did not have enough excess skin to allow traditional abdominoplasty without a high-transverse or vertical midline scar. No umbilical or incisional skin necrosis occurred. To assess optimal umbilical position, plastic surgeons were asked to draw the ideal position on pre- and postoperative photographs from 5 patients. The mean ideal umbilical position was 2.2 cm lower than the actual position (P < 0.01) in preoperative photographs and was close to the true position in postoperative photographs. In conclusion, lower abdominoplasty with inferior umbilical positioning is an excellent choice for the middle age, postpartum woman with excess abdominal skin and full length diastasis recti but a normal body mass index.

Entities:  

Mesh:

Year:  2010        PMID: 20395799     DOI: 10.1097/SAP.0b013e3181db759c

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  1 in total

1.  Treatment of umbilical hernia and recti muscles diastasis without a periumbilical incision.

Authors:  J Kulhanek; O Mestak
Journal:  Hernia       Date:  2013-01-20       Impact factor: 4.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.